Health CarePharmaceuticals and Biotechnology
  • Price (EUR)79.00
  • Today's Change1.44 / 1.86%
  • Shares traded234.52k
  • 1 Year change-23.93%
  • Beta0.5232
Data delayed at least 15 minutes, as of Mar 21 2023 16:35 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

  • Revenue in EUR (TTM)5.52bn
  • Net income in EUR420.00m
  • Incorporated--
  • Employees8.70k
  • Location
    Ucb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
  • Phone+32 25599999
  • Fax+32 25599900
  • Websitehttps://www.ucb.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Recordati Industria Chimica e Farma SpA1.85bn312.34m8.06bn4.30k25.685.1218.404.351.501.508.907.520.54391.745.53--9.1712.8211.8616.3869.4271.0516.8522.480.811415.900.526161.8417.297.55-19.081.5845.876.23
Ipsen SA3.16bn593.20m8.80bn5.74k15.592.609.422.796.747.3234.7540.450.59562.105.27--11.209.9114.7813.8083.2882.0018.8115.231.5847.090.190421.115.249.43-8.2617.050.98543.71
Qiagen NV2.00bn394.82m9.74bn6.18k24.742.9916.534.871.721.728.6814.200.34442.216.03323,383.806.815.048.516.0264.6565.3919.7615.542.0930.330.3494---4.898.60-17.44--3.72--
Croda International Plc2.39bn743.60m10.28bn5.83k13.843.7211.604.304.654.6514.9617.300.60512.435.85358,678.1018.9212.8522.0415.0547.1745.6131.2720.161.4323.800.202148.6310.578.76102.4023.14-0.88175.41
BioMerieux SA3.59bn452.40m11.51bn13.08k25.493.1918.903.213.823.8230.2830.490.73312.335.39--9.009.8711.5713.1655.9755.9612.2712.941.31266.910.121817.016.319.42-24.7413.709.3320.11
Eurofins Scientific SE6.71bn658.20m11.69bn61.38k18.352.449.851.743.312.9233.7324.840.691434.684.92109,355.007.047.708.719.7022.5423.8010.1811.581.228.080.406719.13-0.083417.70-34.7320.1421.8533.03
UCB SA5.52bn420.00m15.09bn8.70k35.951.6214.942.732.162.1528.6947.810.36691.884.82633,919.302.796.233.487.8269.6673.497.6114.760.77029.120.242431.62-4.504.02-60.19-11.0012.162.42
argenx SE383.19m-661.99m18.59bn843.00--7.07--48.51-12.22-12.227.0947.390.13730.17442.94454,558.90-23.71-21.60-26.37-24.3092.83---172.76-188.608.42-80.200.0044---17.4058.50-73.81--204.62--
Merck KGaA22.23bn3.33bn21.16bn64.23k21.432.794.120.95167.647.6451.0959.630.47362.005.49346,120.307.
Genmab A/S1.96bn741.92m22.20bn1.66k29.915.97--11.3283.7283.72221.20419.770.5317--3.158,792,169.0020.1119.2721.4420.51----37.8340.71----0.0213--72.0743.9083.5837.9929.07--
Data as of Mar 21 2023. Currency figures normalised to Ucb SA's reporting currency: Euro EUR

Institutional shareholders

21.06%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 30 Dec 202220.07m10.32%
Fidelity Management & Research Co. LLCas of 31 Jan 20234.07m2.09%
The Vanguard Group, Inc.as of 03 Mar 20233.39m1.74%
Norges Bank Investment Managementas of 31 Dec 20223.01m1.55%
BlackRock Fund Advisorsas of 01 Mar 20232.85m1.47%
Baillie Gifford & Co.as of 16 Mar 20231.94m1.00%
Artisan Partners LPas of 31 Dec 20221.51m0.78%
BlackRock Advisors (UK) Ltd.as of 02 Mar 20231.47m0.76%
Amundi Asset Management SA (Investment Management)as of 14 Mar 20231.46m0.75%
Degroof Petercam Asset Management SAas of 30 Nov 20221.19m0.61%
More ▼
Data from 31 Dec 2022 - 14 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.